Thu, Oct 23, 2014, 6:24 AM EDT - U.S. Markets open in 3 hrs 6 mins

Recent

% | $
Quotes you view appear here for quick access.

Insmed Incorporated Message Board

  • mdplanet@ymail.com mdplanet Jul 26, 2013 6:49 PM Flag

    Seriously Folks...

    Sorry, but this MB makes me laugh.

    Anyone who thinks that a secondary should be based upon analyst ratings is lost. These ratings are provided to help understand the longer term future of the stock and should be taken with a grain of salt as most analysts are loyal to their company and their company ONLY. They don't care about retail trader Joe.

    The run up in May was WAY overdone. Think about it, a 50+% increase since mid May and 100+% since February. What did you people expect? This thing was trading at less than $6 six months ago and you all thought it would reach $20 in a millisecond. The run up was due to anticipation of the results, nothing more. As "compelling" as they were, they were not good enough to keep the stock trading at the $12-13 level as questions still exist as to the future.

    And the secondary...look at the moving averages, about where it should have been. Please stop with these allegations and look at the big picture.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • 19users liked this postsusers disliked this posts13Reply
      Seriously Folks...
      by mdplanet • Jul 26, 2013 6:49 PM Flag
      Sorry, but this MB makes me laugh.

      Anyone who thinks that a secondary should be based upon analyst ratings is lost. These ratings are provided to help understand the longer term future of the stock and should be taken with a grain of salt as most analysts are loyal to their company and their company ONLY. They don't care about retail trader Joe.

      The run up in May was WAY overdone. Think about it, a 50+% increase since mid May and 100+% since February. What did you people expect? This thing was trading at less than $6 six months ago and you all thought it would reach $20 in a millisecond. The run up was due to anticipation of the results, nothing more. As "compelling" as they were, they were not good enough to keep the stock trading at the $12-13 level as questions still exist as to the future.

      And the secondary...look at the moving averages, about where it should have been. Please stop with these allegations and look at the big picture

      • 1 Reply to insm_truth_teller
      • 19users liked this postsusers disliked this posts13Reply
        Seriously Folks...
        by mdplanet • Jul 26, 2013 6:49 PM Flag
        Sorry, but this MB makes me laugh.

        Anyone who thinks that a secondary should be based upon analyst ratings is lost. These ratings are provided to help understand the longer term future of the stock and should be taken with a grain of salt as most analysts are loyal to their company and their company ONLY. They don't care about retail trader Joe.

        The run up in May was WAY overdone. Think about it, a 50+% increase since mid May and 100+% since February. What did you people expect? This thing was trading at less than $6 six months ago and you all thought it would reach $20 in a millisecond. The run up was due to anticipation of the results, nothing more. As "compelling" as they were, they were not good enough to keep the stock trading at the $12-13 level as questions still exist as to the future.

        And the secondary...look at the moving averages, about where it should have been. Please stop with these allegations and look at the big picture

    • mdplanet@ymail.com mdplanet Jul 26, 2013 10:34 PM Flag

      Listen, my friend, potential sales of Arikace are expected to peak at $600M in 2020. Get it, 2020, seven years from now. Must I repeat, 7 years, potential. I won't pretend to offer anything more. Can I give an anonymous, retailer unbiased, present day valuation? I won't lie, I can't and won't state as such. But what I do know is, at this stage in the game, a +/- $400M market cap for a company who has yet to have an approved drug sounds about right, especially as it is only the EU and Canada that offer the best chance for approval, not the US at this point. Do you honestly think it should be higher, closer to $1B? I think not.

      Don't blame the analysts because you may have chased this up or perhaps bought pre-reverse split and have suffered since, hoping the PH3 results would be your saving grace. It is what it is, and as I see it, it's pretty doggone fair.

      • 5 Replies to mdplanet
      • mdplanet ! So you still think people who bought pre-reversed spilt ($5-$6) and sold and/or still hold on to the shares have still suffered ?! Strange indeed ! I sold some in June 11 to get 100+% return. One of the Director bought almost 100000+ shares @ $5 / share around that time, I don't think he has suffered at all !!!!!!! So you may bought in before the first pre-reverse spilt then. If you bought a few weeks pre & post of 2nd reverse spilt you could be in green now. 2+ years after the split, and there still are people think it's bad when it's still more than 100% return as of last Friday.

      • mdplanet • Jul 26, 2013 10:34 PM Flag
        18users liked this postsusers disliked this posts12Reply
        Listen, my friend, potential sales of Arikace are expected to peak at $600M in 2020. Get it, 2020, seven years from now. Must I repeat, 7 years, potential. I won't pretend to offer anything more. Can I give an anonymous, retailer unbiased, present day valuation? I won't lie, I can't and won't..

      • mdplanet, You said:"Don't blame the analysts because you may have chased this up or perhaps bought pre-reverse split and have suffered since ....." Do you mean investors who bought shares from 1-3-11 to 3-3-11 ( date of R/S) or form the merger in 2010 to 3-3-11 or from Jan-2009 to 3-3-11 or you only meant who bought INSM before July 2000? TIA.

      • I agree with the jist of your post,share your revenue and timeline projections.Where did you get those numbers? They are optimistic,if only for the fact that no NTM results are seen.

      • mdplanet, ! be prepared to answer my complaint from the SEC! - )
        You have impersonating a rational investor in this company and personally I think you are involved with the "dark pools of naked hedge fund Money!

        You will soon be called "basher" or worse ! terry_insm - ) !. .... Good post.
        Yahoo boards are filled with dreamers and naivete in biotech so "this board" is common among message boards...long term holders are not laughing...... I find the board a very accurate sentiment indicator.(contrarion)

        7 years and 600 M is an optimistic and then successful biotech company that surely will be a buyout candidate imho.....perhaps the next 7 months will tell the tale and can set up good trades.
        The biggest is of course is the NTM results which will make or break this stock imho. Probably first quarter 2014.......Near term is the 68 million and what they intend to do with the money.....Do they trial in the U.S. or expand the pipeline? .... my guess is a P3 US FDA trial....

        As the share price falls to more realistic levels,reality will come to this board......its already started
        Good Luck

    • "The run up in May was WAY overdone."

      If I'm any judge of character you're now going to prove to us you're only PRETENDING to have a clue - by being COMPLETELY UNABLE to offer us a credible calculation of present market value based upon projected revenue.

      Try again when you have some basic knowledge about valuation.

 
INSM
13.91+0.28(+2.05%)Oct 22 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.